Contact
Please use this form to send email to PR contact of this press release:
Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics”
TO:
Mark Jackson
Paras Biopharmaceuticals Finland Oy
+358 44 2905993